Skip to main content
. 2019 Sep 9;37(35):3350–3358. doi: 10.1200/JCO.19.00345

FIG 3.

FIG 3.

Kaplan-Meier estimates of overall survival (OS) over the 36-month period since random assignment and restricted mean OS according to treatment group. IPI, ipilimumab; NIVO, nivolumab.